Skip to main content
Hematologic Cancer Multiple Myeloma

Multiple Myeloma

Free for a limited time Multiple Myeloma Review

Managing kidney injury caused by multiple myeloma

Up to half of patients with multiple myeloma can have renal injury at initial diagnosis. What are the underlying mechanisms, diagnostic approaches, and treatment strategies?

Editor's Choice

DREAMM-8 supports use of novel ADC in multiple myeloma

12-06-2024 Multiple Myeloma News

A combination incorporating the antibody–drug conjugate belantamab mafodotin significantly improves the outcomes of people with relapsed or refractory multiple myeloma.

Digital interventions in hematologic malignancies

Learn how digital technology via the use of web-based and smart device apps, remote monitoring devices, and patient portals, can improve the care of adult and pediatric patients with hematologic cancers.

Early results point to potential of novel oral agent in multiple myeloma

06-09-2023 Multiple Myeloma News

Mezigdomide has shown promising antitumor activity in combination with dexamethasone in a phase 1/2 trial comprising patients with relapsed and refractory multiple myeloma.

Response-adapted therapy for multiple myeloma

Response-adapted treatment algorithms have the potential to allow an individualised treatment strategy – maximising efficacy, while minimising toxicities and cost – in newly diagnosed multiple myeloma.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare

Case-Based Insights: Oncology and Hematology (Link opens in a new window)


Refresh your knowledge in Oncology and Hematology: 

  • 45 clinical cases across different topics with relevant clinical images
  • Written by renowned experts 
  • Knowledge-check questions with answers
Try the first set of cases now

Current Reviews

Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it

Open Access Magnetic Resonance Imaging Review Article

Metastatic disease and myeloma present unique diagnostic challenges due to their multifocal nature. Accurate detection and staging are critical for determining appropriate treatment. Bone scintigraphy, skeletal radiographs and CT have long been …

Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy

Transcripts longer than 200 nucleotides that are not translated into proteins are known as long non-coding RNAs, or lncRNAs. Now, they are becoming more significant as important regulators of gene expression, and as a result, of many biological …

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models

Open Access Dexamethasone Systematic Review

Multiple myeloma (MM) is a rare incurable hematological cancer that forms in plasma cells, a type of white blood cell that produces antibodies [ 1 ]. As malignant plasma cells accumulate in the bone marrow, they eventually lead to bone destruction …

TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma

Open Access Multiple Myeloma Review

Although substantial quantities of potent therapies for multiple myeloma (MM) have been established, MM remains an incurable disease. In recent years, our understanding of the initiation, development, and metastasis of cancers has made a …

CME & eLearning

Cases

Take on interactive case studies with a focus on hematology. Each case has been prepared by renowned experts in the field and features knowledge-check questions with answers to help keep you and your practice up to date.

Developed by: Springer Medizin

Further Reading

Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it

Open Access Magnetic Resonance Imaging Review Article

Metastatic disease and myeloma present unique diagnostic challenges due to their multifocal nature. Accurate detection and staging are critical for determining appropriate treatment. Bone scintigraphy, skeletal radiographs and CT have long been …

R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study

Open Access Multiple Myeloma Research

We aimed to evaluate if circulating plasma cells (CPC) detected by flow cytometry could add prognostic value of R2-ISS staging. We collected the electronic medical records of 336 newly diagnosed MM patients (NDMM) in our hospital from January 2017 …

The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study

Open Access Multiple Myeloma Research

Multiple myeloma (MM) is an incurable malignancy of plasma cells in the bone marrow and is the second most common haematological malignancy, with incidence set to rise due to an ageing population [ 1 , 2 ]. Patients with MM often experience high …

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Open Access Multiple Myeloma Research

The prognosis of multiple myeloma (MM) patients has been dramatically improved by proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies [ 1 – 5 ]. Among them, isatuximab, one of the new anti-CD38 antibodies, has shown a high …